Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19

Clinical Immunology(2021)10.1016/j.clim.2021.108716Source: DataRank Database

Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19 is a research paper published in Clinical Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 64 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access64 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 3.65)OA: greenTopics (71)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Maria Tsokos ORCID,Olga R. Brook ORCID,Jonathan L. Hecht ORCID,Vaishali R. Moulton ORCID,George C. Tsokos ORCID

Live enrichment

PubMed:33774179 PMC:PMC7989127 OpenAlex:https://openalex.org/W3139442136

National Institute of Allergy and Infectious Diseases

Grant: 1R21AI151367-01A1

Intracellular complement activation in Lupus Nephritis Podocytes

NIAID NIH HHS

Grant: R21 AI151367

National Institutes of Health

FWCI

3.65

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7989127

publisherhttps://api.elsevier.com/content/article/PII:S152166162100053X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S152166162100053X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clim.2021.108716

Fields of Study

COVID-19 Clinical Research StudiesCOVID-19 Impact on ReproductionSARS-CoV-2 and COVID-19 Research0301 basic medicine0303 health sciences03 medical and health sciencesAgedAged, 80 and overCOVID-19Complement ActivationComplement Inactivating AgentsComplement Pathway, AlternativeEpithelial CellsFemaleHumansImmunohistochemistryLungLung InjuryMaleMiddle Aged

MeSH Terms

COVID-19AgedAged, 80 and overComplement ActivationComplement Pathway, AlternativeEpithelial CellsFemaleHumansImmunohistochemistryLungMaleMiddle AgedComplement Inactivating AgentsLung Injury

Keywords

Complement (music)Coronavirus disease 2019 (COVID-19)Complement systemAlternative complement pathwayPathogenesisLungImmunologyInflammation2019-20 coronavirus outbreakMedicineClassical complement pathwaySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyBiologyPathologyImmune systemDiseaseInternal medicineGeneticsOutbreakPhenotypeLung injuryImmune complexesComplement activationCovid-19Sars-cov-2Aged, 80 and overMaleComplement Pathway, AlternativeEpithelial CellsMiddle AgedBrief CommunicationImmunohistochemistryComplement Inactivating AgentsHumansFemaleAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377.v1figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380.v1figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386.v1figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389.v1figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392.v1figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395.v1figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401.v1figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401figshare